


200290"STB6600T

Comparison of antitumor activity of a humanized anti-CD40 antibody and
 a humanized anti-CD20 antibody against Ramos lymphoma transplanted in SCID mice



00-462
 001110

Day 21 Post Treatment

Start on d13
 4mg/kg/3 times/wk
 (3 doses)

FIG. 1





FIG._2


Antitumor activity of a humanized anti-CD20 antibody and humanized anti-CD40 antibody against IM9, (CD20+, CD40+Multiple myeloma) transplanted in SCID mice




00-529
 110300
 Days Post Tumor Implant
 Start on d3
 4mg/kg/3 times/wk (9 doses)

FIG._3

Combination of a humanized anti-CD20 antibody and a murine anti-CD40 antibody (SGN-14) for antitumor activity Against H.S. Sultan, (CD20+, CD40+Multiple myeloma) transplanted in SCID mice



Anti-tumor activity of a murine anti-CD40 antibody (SGN-14) and an anti-CD20 antibody (RITUXAN®, brand) on **RITUXAN®, brand resistant Ramos Lymphoma** transplanted in SCID mice



Start on d13
 4mg/kg/3 times/wk (9 doses)

FIG._5